Tenaya Therapeutics (NASDAQ:TNYA - Free Report) had its price target cut by Canaccord Genuity Group from $18.00 to $16.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.
Several other equities research analysts also recently issued reports on TNYA. HC Wainwright restated a buy rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a report on Wednesday. Chardan Capital reaffirmed a buy rating and issued a $20.00 price target on shares of Tenaya Therapeutics in a research note on Thursday, March 21st. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of Buy and an average target price of $15.00.
Read Our Latest Report on Tenaya Therapeutics
Tenaya Therapeutics Price Performance
Tenaya Therapeutics stock remained flat at $4.25 during midday trading on Thursday. 356,452 shares of the company traded hands, compared to its average volume of 497,017. The stock has a market capitalization of $333.71 million, a PE ratio of -2.55 and a beta of 2.61. The firm has a 50 day moving average price of $4.73 and a two-hundred day moving average price of $3.88. Tenaya Therapeutics has a twelve month low of $1.66 and a twelve month high of $8.09.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. On average, research analysts forecast that Tenaya Therapeutics will post -1.7 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, insider Timothy Hoey sold 6,569 shares of the company's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $5.34, for a total value of $35,078.46. Following the sale, the insider now directly owns 236,146 shares of the company's stock, valued at approximately $1,261,019.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Faraz Ali sold 6,358 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $5.86, for a total value of $37,257.88. Following the transaction, the chief executive officer now owns 113,079 shares in the company, valued at approximately $662,642.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Timothy Hoey sold 6,569 shares of the business's stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $5.34, for a total value of $35,078.46. Following the sale, the insider now owns 236,146 shares of the company's stock, valued at approximately $1,261,019.64. The disclosure for this sale can be found here. Insiders have sold 20,908 shares of company stock valued at $122,867 in the last 90 days. 32.76% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its stake in shares of Tenaya Therapeutics by 10.7% in the third quarter. RA Capital Management L.P. now owns 6,718,483 shares of the company's stock valued at $17,132,000 after buying an additional 651,000 shares during the period. Vanguard Group Inc. grew its holdings in shares of Tenaya Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company's stock worth $14,973,000 after purchasing an additional 403,472 shares in the last quarter. Euclidean Capital LLC increased its position in shares of Tenaya Therapeutics by 10.9% in the third quarter. Euclidean Capital LLC now owns 1,015,705 shares of the company's stock worth $2,590,000 after purchasing an additional 100,000 shares during the period. GSA Capital Partners LLP raised its stake in Tenaya Therapeutics by 194.5% in the third quarter. GSA Capital Partners LLP now owns 363,493 shares of the company's stock valued at $927,000 after purchasing an additional 240,082 shares in the last quarter. Finally, Barclays PLC lifted its position in Tenaya Therapeutics by 2,635.8% during the third quarter. Barclays PLC now owns 249,558 shares of the company's stock worth $637,000 after purchasing an additional 240,436 shares during the period. 90.54% of the stock is owned by institutional investors and hedge funds.
Tenaya Therapeutics Company Profile
(
Get Free Report)
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
Featured Articles
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
